See more : TAAL Enterprises Limited (TAALENT.BO) Income Statement Analysis – Financial Results
Complete financial analysis of Voyageur Pharmaceuticals Ltd. (VYYRF) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Voyageur Pharmaceuticals Ltd., a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
You may be interested
- Adtiger Corporations Limited (1163.HK) Income Statement Analysis – Financial Results
- DSR Wire Corp (069730.KS) Income Statement Analysis – Financial Results
- Sezzle Inc. (SEZL) Income Statement Analysis – Financial Results
- Corporate Travel Management Limited (CTMLF) Income Statement Analysis – Financial Results
- Verbund AG (OEWA.DE) Income Statement Analysis – Financial Results
Voyageur Pharmaceuticals Ltd. (VYYRF)
Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Website: https://voyageurpharmaceuticals.ca
About Voyageur Pharmaceuticals Ltd.
Voyageur Pharmaceuticals Ltd. focuses on the development of active pharmaceutical ingredients minerals. The company intends to develop barium and iodine radiocontrast products and bromine based pharmaceutical products. It holds 100% interest in three barium sulfate deposits, including two properties suitable in grade for the pharmaceutical barite marketplace located in British Columbia, Canada; and interests in a high-grade iodine, lithium, and bromine brine project in Utah, the United States. The company was formerly known as Voyageur Minerals Ltd. and changed its name to Voyageur Pharmaceuticals Ltd. in December 2019. Voyageur Pharmaceuticals Ltd. is headquartered in Calgary, Canada.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 2.19K | 2.91K | 2.25K | 1.48K | 2.12K | 0.00 | 0.00 | 113.54K | 137.22K | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -2.19K | -2.91K | -2.25K | -1.48K | -2.12K | 0.00 | 0.00 | -113.54K | -137.22K | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 0.00 | 527.56K | 496.51K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 376.16K | 1.22M | 1.55M | 999.56K | 552.77K | 866.03K | 655.74K | 571.39K | 108.83K | 0.00 | 45.33K | 85.52K | 0.00 |
| Selling & Marketing | 280.94K | 527.56 | 496.51 | 0.00 | 0.00 | 0.00 | 0.00 | -519.07K | -107.35K | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 1.22M | 1.22M | 1.55M | 999.56K | 552.77K | 866.03K | 655.74K | 52.32K | 1.48K | 94.46K | 45.33K | 85.52K | 0.00 |
| Other Expenses | 0.00 | 0.00 | 0.00 | 13.73K | 2.60K | 26.88K | 40.38K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 1.22M | 1.75M | 2.05M | 1.00M | 554.89K | 866.03K | 655.74K | 52.32K | 1.48K | 94.46K | 45.33K | 85.52K | 0.00 |
| Cost & Expenses | 1.22M | 1.75M | 2.05M | 1.00M | 554.89K | 866.03K | 655.74K | 52.32K | 1.48K | 94.46K | 45.33K | 85.52K | 0.00 |
| Interest Income | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 0.00 | 0.00 | 3.28K | 18.65K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 2.19K | 2.91K | 2.25K | 1.48K | 2.12K | 845.76K | 615.01K | 698.17K | 246.05K | 0.00 | 0.00 | 0.00 | 0.00 |
| EBITDA | -1.22M | -1.75M | -2.05M | -1.12M | -550.17K | 0.00 | 0.00 | -520.00 | 0.00 | -94.46K | -45.33K | -85.52K | 0.00 |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -1.22M | -1.75M | -2.05M | -848.94K | -554.89K | -1.15M | -615.36K | -52.32K | -1.48K | -94.46K | -45.33K | -85.52K | 0.00 |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | -178.52K | -1.97K | -3.28K | -154.84K | -21.83K | 289.90K | -55.74K | -516.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Income Before Tax | -1.40M | -1.75M | -2.05M | -1.14M | -552.29K | -555.86K | -670.75K | -52.32K | -1.48K | -94.46K | -45.33K | -85.52K | 0.00 |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | 1.97K | -1.00 | 152.10K | -169.74K | -444.43K | -40.38K | -5.49K | -246.06K | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Income | -1.40M | -1.75M | -2.05M | -1.14M | -552.29K | -555.86K | -670.75K | -52.32K | -1.48K | -94.46K | -45.33K | -85.52K | 0.00 |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -0.01 | -0.02 | -0.02 | -0.02 | -0.01 | -0.01 | -0.02 | -0.05 | 0.00 | -0.09 | -0.05 | -0.14 | 0.00 |
| EPS Diluted | -0.01 | -0.02 | -0.02 | -0.02 | -0.01 | -0.01 | -0.02 | -0.05 | 0.00 | -0.09 | -0.05 | -0.14 | 0.00 |
| Weighted Avg Shares Out | 130.51M | 107.83M | 94.68M | 70.53M | 57.54M | 47.52M | 36.40M | 1.01M | 1.01M | 1.01M | 1.01M | 626.52K | 925.00K |
| Weighted Avg Shares Out (Dil) | 130.50M | 107.83M | 94.68M | 70.53M | 57.54M | 47.52M | 36.40M | 1.01M | 1.01M | 1.01M | 1.01M | 626.52K | 925.00K |
Voyageur Pharmaceuticals launches C$1M private placement
Voyageur Pharmaceuticals Ltd (TSX-V:VM, OTC:VYYRF) announced a proposed non-brokered private placement aiming to raise up to C$1 million by issuing 16,666,667 units at C$0.06 per unit. Each unit consists of one common share and one warrant exercisable at C$0.10 for 36...
Voyageur Announces Proposed Private Placement
Calgary, Alberta--(Newsfile Corp. - October 17, 2024) - Voyageur Pharmaceuticals Ltd. (TSXV: VM) (OTC Pink: VYYRF) ("Voyageur" or the "Corporation"), is pleased to announce a proposed non-brokered private placement of up to 16,666,667 units ("Units") at a price of $0.06...
Voyageur Pharmaceuticals Grants Stock Options
Calgary, Alberta--(Newsfile Corp. - September 25, 2024) - Voyageur Pharmaceuticals Ltd. (TSXV: VM) (OTC Pink: VYYRF) ("Voyageur" or the "Company") announces that it has granted an aggregate of 600,000 stock options (the "Options") to officers of the Company pursuant to its...
Voyageur Pharmaceuticals adds new vice president of business development
Voyageur Pharmaceuticals Ltd (TSX-V:VM, OTC:VYYRF) announced the appointment of Dr Ibrahim Hashmi as Vice President of Business Development to accelerate the company's commercial initiatives and expand its global presence in the medical imaging industry. According to Voyageur, Hashmi brings over 25...
Voyageur Pharmaceuticals welcomes new chief science officer
Voyageur Pharmaceuticals Ltd (TSX-V:VM, OTC:VYYRF) announced it is adding to its executive team with the appointment of Dr Iryna Saranchova as its new chief science officer. Saranchova joins Voyageur from her previous role as chief clinical officer at MYND Life...
Voyageur Pharmaceuticals completes formulation of innovative diagnostic products, eyes FDA approval
Voyageur Pharmaceuticals Ltd (TSX-V:VM, OTC:VYYRF) announced the completion of formulation work on a new product line, consisting of five Health Canada licensed barium contrast agents for medical diagnostics. The products, developed under the distinct brands Vision and Smooth, aim to...
Voyageur Pharmaceuticals CEO shares major progress in MRI drug innovation with Rain Cage
Voyageur Pharmaceuticals Ltd (TSX-V:VM, OTC:VYYRF) earlier this week announced significant progress in their collaboration with Rain Cage. The company disclosed that Rain Cage has successfully created vanadium metal fullerenes at scale, a world-first achievement.
Voyageur Pharmaceuticals announces new collaboration with Rain Cage Carbon
Voyageur Pharmaceuticals Ltd (TSX-V:VM, OTC:VYYRF) has announced a collaboration with Rain Cage Carbon Inc to develop advanced radiology contrast agents. The partnership will focus on the commercial-scale production of gadolinium, bismuth, and iodine encapsulated within endohedral fullerenes.
Voyageur Pharmaceuticals announces collaboration with Rain Cage Carbon
Voyageur Pharmaceuticals Ltd (TSX-V:VM, OTC:VYYRF) has announced a collaboration with Rain Cage Carbon Inc to develop advanced radiology contrast agents. The partnership will focus on the commercial-scale production of gadolinium, bismuth, and iodine encapsulated within endohedral fullerenes.
Voyageur Pharmaceuticals partner Rain Cage Carbon and Toyota Tsusho Canada forge alliance for sustainable automotive solutions
Voyageur Pharmaceuticals Ltd (TSX-V:VM, OTC:VYYRF) strategic partner Rain Cage Carbon Inc has announced a landmark co-marketing and master purchase agreement with Toyota Tsusho Canada Inc., a prominent supplier to global vehicle manufacturers and parts suppliers. The collaboration aims to integrate...
Source: https://incomestatements.info
Category: Stock Reports